Logo image
Back
CORE-008 cohort B: Evaluating intravesical cretostimogene grenadenorepvec in patients with high-risk, BCG-exposed non-muscle invasive bladder cancer
Journal article   Peer reviewed

CORE-008 cohort B: Evaluating intravesical cretostimogene grenadenorepvec in patients with high-risk, BCG-exposed non-muscle invasive bladder cancer

Trinity Bivalacqua, Siamak Daneshmand, Eugene Cone, Christopher Michael Pieczonka, Laurence Belkoff, Matthew Mossanen, Vikram M. Narayan and Gary D. Steinberg
Journal of clinical oncology, v 44(7_suppl), TPS896
Mar 2026
DOI: https://doi.org/10.1200/JCO.2026.44.7_suppl.TPS896

Abstract

TPS896 Background: Patients with High-Risk NMIBC whose disease trajectory falls outside the strict FDA guidance of BCG-Unresponsive represent a significant unmet need, often lacking access to clinical trials or evidence-based treatment options. Cretostimogene grenadenorepvec is an oncolytic immunotherapy with dual mechanisms of action. It replicates in and lyses cancer cells with Retinoblastoma (Rb)-E2F pathway alterations, while simultaneously amplifying an anti-tumor immune response, further mediated by the GM-CSF transgene. The CORE-008 clinical trial (NCT06567743) is a Phase 2, multi-arm, multi-cohort trial to evaluate the efficacy and safety of cretostimogene in patients with HR NMIBC, across BCG-naïve, BCG-exposed, and BCG-unresponsive disease states. Here, we describe Cohort B of CORE-008, which examines the efficacy and safety of cretostimogene in BCG-exposed NMIBC. Methods: Cohort B eligibility criteria include pathologic confirmation of HR NMIBC, CIS containing and papillary only, as defined by the AUA/SUO guidelines, and recurrence after prior BCG. BCG-exposed NMIBC is defined as high-grade recurrence in patients who are BCG-resistant (recurrence after at least 5 of 6 induction doses), or who experience delayed relapse within 24 months following either adequate BCG (≥5 induction doses plus ≥2 reinduction or maintenance doses) but outside the defined BCG-Unresponsive window or following inadequate BCG (3–6 doses). Intravesical cretostimogene is instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by three weekly maintenance cycles quarterly through Month 12, then every six months through Month 36. Re-induction is permitted at Month 3, if persistent HG Ta or CIS is noted at biopsy. Response assessment includes serial cystoscopy with directed biopsy (as indicated), urine cytology, and CT/MR urogram. The primary endpoint for the CIS population is Complete Response (CR) at any time and HG-EFS for patients with papillary-only disease. Secondary endpoints include Duration of Response, all-cause Event-Free Survival, Bladder Cancer Specific Survival, Progression-Free Survival, Cystectomy-Free Survival, safety, and tolerability. Exploratory outcome measures consist of Health-Related Quality of Life, Overall Survival, and biomarker assessments. Cohort B is open for enrollment in collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC). Clinical trial information: NCT06567743 .

Metrics

1 Record Views

Details

Logo image